



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

December 25, 2020

To The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code- 532523	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Symbol- Biocon
--	--

Dear Sir/Madam,

Subject: Biocon Biologics Statement on the Status of Bevacizumab FDA Action Date in Dec 2020

Please find below the “Company Statement” on the subject matter.

“This is to inform you that Biocon Biologics Limited, (a subsidiary of Biocon Limited) and Mylan (a subsidiary of Viartis Inc.) have been informed by the U.S. Food and Drug Administration (FDA) of a deferred action on the Biologics License Application (BLA) for MYL-14020, a proposed biosimilar to Avastin® (bevacizumab).

To complete the application, the Agency noted that an inspection of the manufacturing facility is required as a part of the standard review process. However, due to restrictions on travel related to COVID-19, the Agency is unable to conduct an inspection during the current review cycle. We await the dates for the inspection.

There are no additional observations related to the application.” **Company Spokesperson, Biocon Biologics**

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**



Mayank

Mayank Verma
Company Secretary and Compliance Officer